阿仑膦酸钠的严重不良反应,小心!
骨质疏松的患者,在临床上并不少见,近些年双膦酸盐类「BPs」药物(一种强有力的骨吸收抑制剂)的应用也逐渐广泛起来,目前临床上常用的是第二、三代,如唑来膦酸、阿仑膦酸、帕米膦酸等。
![](http://pic.ikafan.com/imgp/L3Byb3h5L2h0dHBzL2ltYWdlMTA5LjM2MGRvYy5jbi9Eb3dubG9hZEltZy8yMDIxLzA0LzA2MjMvMjE5NDgxODc4XzFfMjAyMTA0MDYxMTQ0MjA4MQ==.jpg)
1
●
颌骨坏死「ONJ」
2
●
双膦酸盐相关颌骨坏死「BRONJ」
![](http://n4.ikafan.com/assetsj/blank.gif)
![](http://n4.ikafan.com/assetsj/blank.gif)
![](http://n4.ikafan.com/assetsj/blank.gif)
![](http://n4.ikafan.com/assetsj/blank.gif)
![](http://n4.ikafan.com/assetsj/blank.gif)
(5).使用替代药物特立帕肽进行有效治疗 [14]。
往 期 精 彩
![](http://n4.ikafan.com/assetsj/blank.gif)
![](http://n4.ikafan.com/assetsj/blank.gif)
![](http://n4.ikafan.com/assetsj/blank.gif)
![](http://n4.ikafan.com/assetsj/blank.gif)
— 参考文献 —
1.Watts NB, Marciani RD. Osteonecrosis of the jaw. South Med J. 2008;101(2):160-165.
2.Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-1117.
3. 阿仑膦酸片(福善美)药品说明书. 批准文号:H20130241, 默沙东.
4.https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202344s015lbl.pdf
5.Stavropoulos A, Bertl K, Pietschmann P,et al. The effect 280 of antiresorptive drugs on implant therapy: Systematic review and meta-analysis. Clin 281Oral Implants Res. 2018;29 Suppl 18:54-92.
6.Chaurand-Lara J, Pacheco-Ruiz L, Trejo-Campos JL,et al . Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study. Incidencia de osteonecrosis de los maxilares por el uso de inhibidores de osteoclastos en pacientes con metástasis óseas: estudio de cohorte retrospectivo. Cir Cir. 2019;87(4):396-401.
7. Lee YK, Ha YC, Park C,et al.Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int. 2013;24:707-711.
8. Lee JK, Kim KW, Choi JY, et al. Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report. J Korean Assoc Oral Maxillofac Surg. 2013;39:9-13.
8.Kishimoto H, Noguchi K, Takaoka K. Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Jpn Dent Sci Rev. 2019;55(1):95-102.
9.Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O』Ryan F, et al.Internationaltask force onosteonecrosis ofthe jaw. Diagnosis andmanagement of osteonecrosis of the jaw: a systematic review and international consensus.J Bone Mineral Res 2015;30(1):3–23.
10.Park WB, Herr Y, Kwon YD, et al. Advanced peri-implantitis and implant removal as risk factors for osteonecrosis of the jaw in patients on oral bisphosphonate therapy. J Oral Implantol. 2020 Nov 18.
11.Pazianas M, Miller P, Blumentals WA, et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007;29(8):1548-1558.
12.Aljohani S, Fliefel R, Ihbe J,et al. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review. J Craniomaxillofac Surg. 2017;45(9):1493-1502.
13.Ruggiero SL, Dodson TB, Fantasia J, et al.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 2014;72(10):1938–56.
14.Zushi Y, Takaoka K, Tamaoka J, et al. Treatment with teriparatide for advanced bisphosphonate-related osteonecrosis of the jaw around dental implants: a case report. Int J Implant Dent 2017;3(1):11.
15.Jian, Pan et al. Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology vol. 35,1 (2017): 29-36. doi:10.7518/hxkq.2017.01.004